MRMD
MariMed Inc.
OTC Markets OTCQBUSDEQUITY
Healthcare
DELAYED
Last price
0.09
▲ 0.01 (11.69%)
MARKET · —
Price
Open
0.08
Prev close
0.08
Day high
0.09
Day low
0.08
Volume
528.59K
Market cap
$34.66M
P/E (TTM)
—
52W range
0.06 – 0.23
Trailing performance
Returnvs SPY
1W
+26.47%
+27.8%
1M
+30.30%
+26.6%
3M
+14.67%
+11.6%
6M
+7.50%
-3.6%
YTD
-8.51%
-20.8%
1Y
-31.20%
-51.2%
3Y
-69.29%
-143.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$34.66M
Enterprise value$123.75M
Revenue (TTM)$163.82M
Gross profit$58.37M
EBITDA$9.82M
Net income$-14.95M
EPS (TTM)$-0.04
Free cash flow$17.74M
Total cash$6.54M
Total debt$90.68M
Book value / share$0.11
Shares outstanding403.04M
Float335.51M
Short % of float—
Dividend yield—
Beta (5Y)1.32
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.87
PEG ratio—
Price / sales—
Price / book0.76
EV / revenue0.76
EV / EBITDA12.60
Gross margin35.63%
Operating margin1.27%
Profit margin-9.13%
Return on equity-24.19%
Return on assets-0.58%
Debt / equity180.72
Current ratio0.92
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $159.83M | $157.96M | $148.60M | $134.01M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $0 | $0 | $0 | $0 |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $0 | $0 | $0 | $0 |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.01 | -0.01 | 0.0% |
| Mar 2026 | -0.01 | -0.01 | 0.0% |
| Dec 2025 | -0.01 | 0.01 | +157.0% |
| Sep 2025 | -0.01 | -0.00 | +20.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.01 | 1 | $41.20M | +1.1% |
| Next quarter | -0.01 | 1 | $39.70M | -4.7% |
| Current year | -0.04 | 1 | $162.40M | +1.6% |
| Next year | -0.03 | 1 | $167.80M | +3.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders14.60%
Held by institutions0.24%
Institutions holding3
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
58.84M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 15, 26 | ALLEN DAVID RICHARD CPA Director |
— | 192.31K | — | Direct |
| Jul 15, 26 | GILDEA EDWARD J Director |
— | 192.31K | — | Direct |
| Jul 15, 26 | SELHUB EVA Director |
— | 173.08K | — | Direct |
| Jul 15, 26 | LEVINE JON R Chief Executive Officer |
— | 30.63K | — | Direct |
| Jul 15, 26 | SHAW TIMOTHY Chief Operating Officer |
— | 42.66K | — | Direct |
| Jul 15, 26 | PINHO MARIO Chief Financial Officer |
— | 88.28K | — | Direct |
| Jul 15, 26 | CRANDALL RYAN Officer |
— | 32.81K | — | Direct |
| Jun 15, 26 | CRANDALL RYAN Officer |
— | 250.00K | — | Direct |
| Jun 12, 26 | ALLEN DAVID RICHARD CPA Director |
— | 75.00K | — | Direct |
| Jun 12, 26 | GILDEA EDWARD J Director |
— | 75.00K | — | Direct |
| Jun 12, 26 | SELHUB EVA Director |
— | 75.00K | — | Direct |
| Jun 8, 26 | CRANDALL RYAN Officer |
— | 54.00K | — | Direct |
| May 29, 26 | LEVINE JON R Chief Executive Officer |
— | 46.88K | — | Direct |
| May 29, 26 | SHAW TIMOTHY Chief Operating Officer |
— | 40.63K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLEN DAVID RICHARD CPA |
Director | 743.45K | Conversion of Exercise of derivative security |
CRANDALL RYAN |
Officer | 1.12M | Conversion of Exercise of derivative security |
GILDEA EDWARD J |
Director | 1.17M | Conversion of Exercise of derivative security |
LEVINE JON R |
Chief Executive Officer | 28.04M | Conversion of Exercise of derivative security |
PINHO MARIO |
Chief Financial Officer | 335.17K | Conversion of Exercise of derivative security |
SELHUB EVA |
Director | 730.75K | Conversion of Exercise of derivative security |
SHAW TIMOTHY |
Chief Operating Officer | 11.41M | Conversion of Exercise of derivative security |
TUCKER KATHLEEN |
Director | 350.00K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
0.07
+22.33% from price
SMA 20
0.07
+27.12% from price
SMA 50
0.07
+26.92% from price
SMA 100
0.07
+19.05% from price
SMA 200
0.08
+7.01% from price
EMA 12
0.07
+20.39% from price
EMA 26
0.07
+24.43% from price
EMA 50
0.07
+23.77% from price
RSI (14)
72.4
Overbought
MACD (12,26,9)
0.00
Hist 0.00
ATR (14)
0.01
7.72% of price
Realised vol 30D
75.6%
Annualised
Bollinger upper
0.08
20, 2σ
Bollinger lower
0.06
20, 2σ
50 / 200 cross
Death
0.07 vs 0.08
Trend bias
Above 200
+7.01%
Risk profile
Beta vs SPY
-0.02
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
75.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-65.0%
Peak to trough
Max drawdown 5Y
-93.8%
Peak to trough
ATR 14
0.01
7.72% of price
Beta (reported)
1.32
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
MariMed delivers record revenue quarter as branded strategy gains momentum
Proactive · 2d ago
MariMed Reports Second Quarter 2026 Earnings
GlobeNewswire · 10d ago
Earnings To Watch: MariMed Inc (MRMD) Q2 2026 -- GF Value Sees 130% Upside
GuruFocus.com · 10d ago
Earnings To Watch: MariMed Inc (MRMD) Q2 2026 -- GF Value Sees 147% Upside
GuruFocus.com · 11d ago
MariMed Embraces Pumpkin Season By Unveiling New Products That Bring Seasonal Autumn Flavors to Cannabis Consumers
GlobeNewswire · 16d ago
MariMed Announces Second Quarter 2026 Earnings Date
GlobeNewswire · 38d ago
MariMed’s Betty’s Eddies™ Expands Core Lineup with New Multi-Vitamin Inspired Betty's Bite-A-Mins
GlobeNewswire · 39d ago
MariMed’s Nature’s Heritage Launches “The Nose Knows” Immersive, Science-Backed Consumer Education Campaign
GlobeNewswire · 46d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.